PD-Rx Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
PD-Rx Pharmaceuticals has been growing earnings at an average annual rate of 22.2%, while the Healthcare industry saw earnings growing at 7% annually. Revenues have been growing at an average rate of 0.7% per year.
Key information
22.2%
Earnings growth rate
22.7%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 0.7% |
| Return on equity | -0.9% |
| Net Margin | -0.5% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How PD-Rx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 21 | 0 | 7 | 0 |
| 30 Jun 22 | 29 | 3 | 7 | 0 |
| 30 Jun 21 | 22 | 2 | 6 | 0 |
| 30 Jun 20 | 21 | 0 | 6 | 0 |
| 30 Jun 19 | 21 | 0 | 8 | 0 |
| 30 Jun 18 | 25 | 1 | 8 | 0 |
| 30 Jun 17 | 26 | 1 | 7 | 0 |
| 30 Jun 16 | 21 | 1 | 7 | 0 |
| 30 Jun 15 | 19 | 1 | 7 | 0 |
| 30 Jun 14 | 29 | 2 | 7 | 0 |
| 30 Jun 13 | 26 | 1 | 6 | 0 |
Quality Earnings: PDRX is currently unprofitable.
Growing Profit Margin: PDRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PDRX is unprofitable, but has reduced losses over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare PDRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PDRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.2%).
Return on Equity
High ROE: PDRX has a negative Return on Equity (-0.87%), as it is currently unprofitable.